Treating hepatitis C: The state of the art

Gastroenterology Clinics of North America

Volumn 33, Issue 1 SUPPL., 2004, Pages 1-9

  Gish, Robert G ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; DOLASETRON MESILATE; DRONABINOL; GROWTH FACTOR; HYDROXYCHLOROQUINE; MEGESTROL ACETATE; MODAFINIL; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; PARACETAMOL; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROCHLORPERAZINE; QUININE; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRIMETHOBENZAMIDE; VENLAFAXINE;

ALOPECIA; ANOREXIA; ARTHRALGIA; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BLOOD TOXICITY; CARDIOTOXICITY; CONCENTRATION LOSS; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CRYOGLOBULINEMIA; DEMOGRAPHY; DEPRESSION; DERMATITIS; DIARRHEA; EPIDEMIOLOGICAL DATA; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; GENOTYPE; HEART ARRHYTHMIA; HEART INFARCTION; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INFECTION; INSOMNIA; INTERSTITIAL PNEUMONIA; IRRITABILITY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LUNG DISEASE; MENTAL INSTABILITY; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PRURITUS; RETINA HEMORRHAGE; RETINOPATHY; REVIEW; RIGOR; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNITED STATES; VIRUS INFECTION; VISUAL IMPAIRMENT; WEIGHT REDUCTION;

EID: 1842665148     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2003.12.006     Document Type: Review

References (44)

1. Alter M.J., Kruszon-Moran D., Nainan O.V., McQuillan G.M., Gao F., Moyer L.A., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 341:1999;556-562.
2. Boyer J.L., Chang E.B., Collyar D.E., DeLeve L.D., Feinberg J., Judge T.A., et al. National Institutes of Health consensus development conference statement: management of hepatitis C. June 10-12 2002. Hepatology. 36:(Suppl 1):2002;S3-S20.
3. Seeff L.B. Natural history of hepatitis C. Hepatology. 26:(Suppl 1):1997;21S-28S.
4. Armstrong G.L., Alter M.J., McQuillan G.M., Margolis H.S. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology. 31:2000;777-782.
5. Wong J.B., McQuillan G.M., McHutchison J.G., Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health. 90:2000;1562-1569.
6. Kim W.R. The burden of hepatitis C in the United States. Hepatology. 36:(Suppl 1):2002;S30-S34.
7. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 358:2001;958-965.
8. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Gonçales F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 347:2002;975-982.
9. Hadziyannis S.J., Cheinquer H., Morgan T., Diago M., Jensen D.M., Sette H. Jr., et al. Peginterferon alpha-2A (40 KD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose. [abstract] J Hepatol. 36:(Suppl 1):2002;3.
10. Ferenci P., Shiffman M.L., Fried M.W., Sulkowski M.S., Haeussinger D., Zarski J.-P., et al. Early prediction of response to 40 kDa peginterferon alfa-2a (PEGASYS) plus ribavirin in patients with chronic hepatitis C (CHC). [abstract] Hepatology. 34:(4 Pt 2):2001;351A.
11. McHutchison J.G., Manns M., Patel K., Poynard T., Lindsay K.L., Trepo C., et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 123:2002;1061-1069.
12. Davis G.L., Wong J.B., McHutchison J.G., Manns M.P., Harvey J., Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 38:2003;645-652.
13. Comanor L., Anderson F., Ghany M., Perrillo R., Heathcote E.J., Sherlock C., et al. Transcription-mediated amplification is more sensitive than conventional PCR-based assays for detecting residual serum HCV RNA at end of treatment. Am J Gastroenterol. 96:2001;2968-2972.
14. Gorrin G., Friesenhahn M., Lin P., Sanders M., Pollner R., Eguchi B., et al. Performance evaluation of the VERSANT HCV RNA qualitative assay by using transcription-mediated amplification. J Clin Microbiol. 41:2003;310-317.
15. Van Thiel D.H., Friedlader L., Molloy P.J., Fagiuoli S., Kania R.J., Caraceni P. Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness. Eur J Gastroenterol Hepatol. 7:1995;165-168.
16. Backmund M., Meyer K., Von Zielonka M., Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology. 34:2001;188-193.
17. Cawthorne C.H., Rudat K.R., Burton M.S., Brown K.E., Luxon B.A., Janney C.G., et al. Limited success of HCV antiviral therapy in United States veterans. Am J Gastroenterol. 97:2002;149-155.
18. Sylvestre D.L. Injection drug use and hepatitis C: from transmission to treatment. Psychiatr Ann. 33:2003;377-382.
19. Poynard T., McHutchison J., Manns M., Trepo C., Lindsay K., Goodman Z., et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 122:2002;1303-1313.
20. Borden E.C., Parkinson D. A perspective on the clinical effectiveness and tolerance of interferon-α Semin Oncol. 25:(Suppl 1):1998;3-8.
21. Dieperink E., Willenbring M., Ho S.B. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry. 157:2000;867-876.
22. Fried M.W. Side effects of therapy of hepatitis C and their management. Hepatology. 36:(Suppl 1):2002;S237-S244.
23. Bodenheimer H.C. Jr., Lindsay K.L., Davis G.L., Lewis J.H., Thung S.N., Seeff L.B. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology. 26:1997;473-477.
24. De Franceschi L., Fattovich G., Turrini F., Ayi K., Brugnara C., Manzato F., et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology. 31:2000;997-1004.
25. Flamm S.L., Eshelman A., Lyons M., Levin A., Gordon S., Muir A., et al. Improved medication adherence with cognitive behavioral therapy in patients receiving pegylated interferon alpha 2b (1.5 mcg/kg wk) + ribavirin (800-1400 mg/d): results of a prospective, randomized, controlled, multi-center trial. [abstract] Hepatology. 36:(4 Pt 2):2002;311A.
26. Dieterich D.T., Wasserman R., Bräu N., Hassanein T.I., Bini E.J., Bowers P.J., et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol. 98:2003;2491-2499.
27. Afdhal N.H., Dieterich D.T., Pockros P.J., Schiff E.R., Shiffman M.L., Sulkowski M.S., et al. Epoetin alfa treatment of anemic HCV-infected patients allows for maintenance of ribavirin dose, increases hemoglobin levels, and improves quality of life vs placebo: a randomized, double-blind, multicenter study [abstract]. Gastroenterology. 124:(4 Suppl 1):2003;A-714.
28. Valentine A.D., Meyers C.A., Kling M.A., Richelson E., Hauser P. Mood and cognitive side effects of interferon-α therapy. Semin Oncol. 25:(Suppl 1):1998;39-47.
29. Zdilar D., Franco-Bronson K., Buchler N., Locala J.A., Younossi Z.M. Hepatitis C, interferon alfa, and depression. Hepatology. 31:2000;1207-1211.
30. Trask P.C., Esper P., Riba M., Redman B. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol. 18:2000;2316-2326.
31. Renault P.F., Hoofnagle J.H., Park Y., Mullen K.D., Peters M., Jones B., et al. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med. 147:1987;1577-1580.
32. McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 339:1998;1485-1492.
33. Davis G.L., Esteban-Mur R., Rustgi V., Hoefs J., Gordon S.C., Trepo C., et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med. 339:1998;1493-1499.
34. Gleason O.C., Yates W.R. Five cases of interferon-alfa-induced depression treated with antidepressant therapy. Psychosomatics. 40:1999;510-512.
35. Schramm T.M., Lawford B.R., Macdonald G.A., Cooksley W.G.E. Sertraline treatment of interferon-alfa-induced depressive disorder. MJA. 173:2000;359-361.
36. Kraus M.R., Schafer A., Faller H., Csef H., Scheurlen M. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther. 16:2002;1091-1099.
37. Hauser P., Khosla J., Aurora H., Laurin J., Kling M.A., Hill J., et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry. 7:2002;942-947.
38. Gleason O.C., Yates W.R., Isbell M.D., Philipsen M.A. An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry. 63:2002;194-198.
39. Dieperink E., Ho S.B., Thuras P., Willenbring M.L. A prospective study of neuropsychiatric symptoms associated with interferon-α-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics. 44:2003;104-112.
40. Loftis J.M., Hauser P. Comanagement of depressive and HCV treatment. Psychiatr Ann. 33:2003;385-391.
41. Goldsmith J., Hauser P. Psychiatric issues in patients with hepatitis C. [editorial] Psychiatr Ann. 33:2003;357-360.
42. Cheung R., Ahmed A. Treating chronic hepatitis C patients with psychiatric disorders: an uphill battle. [editorial] Am J Gastroenterol. 96:2001;3-4.
43. Lehman C.L., Cheung R.C. Depression, anxiety, post-traumatic stress, and alcohol-related problems among veterans with chronic hepatitis C. Am J Gastroenterol. 97:2002;2640-2646.
44. El-Serag H.B., Kunik M., Richardson P., Rabeneck L. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology. 123:2002;476-482.